Skip to Content

Publications Search - Abstract View

Title: IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.
Authors: Martin MP,  Qi Y,  Goedert JJ,  Hussain SK,  Kirk GD,  Hoots WK,  Buchbinder S,  Carrington M,  Thio CL
Journal: J Infect Dis
Date: 2010 Dec 1
Branches: IIB
PubMed ID: 20977343
PMC ID: PMC2974014
Abstract: An IL28B haplotype strongly determines the outcome of natural and interferon-α treated hepatitis C virus (HCV) infection. To assess whether the polymorphism marking the haplotype (rs12979860) also affects other interferon-α responsive chronic viral illnesses, namely hepatitis B virus (HBV) and human immunodeficiency virus (HIV) type 1 infections, we genotyped 226 individuals with HBV persistence, 384 with HBV recovery, and 2548 with or at high risk for HIV infection. The C/C genotype of rs12979860 was not associated with HBV recovery (odds ratio, 0.99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression (P > .05). This IL28B single-nucleotide polymorphism affects the immune response to HCV but not to HBV or HIV.